The information contained in this section of www.ONIVYDE.com is intended for US
healthcare professionals only.
If you are a US healthcare professional, click “OK”
to continue. If you are not a US healthcare professional, click “Cancel” to return to the patient
and caregiver section of the site.
(irinotecan liposome injection)
The first and only therapy FDA-approved
in combination with 5-FU/LV for patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy1,2
**National Comprehensive Cancer Network® (NCCN®).
References: 1. ONIVYDE® Full Prescribing Information. 2. Data on file. Basking Ridge, NJ; Ipsen Biopharmaceuticals, Inc.
INDICATION AND IMPORTANT